729 results on '"Paintaud, Gilles"'
Search Results
2. Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages
3. Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients
4. The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition
5. Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model
6. Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant Patients
7. Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics
8. Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study
9. Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients
10. Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited
11. Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review
12. Intra-tracheal amikacin spray delivery in healthy mechanically ventilated piglets
13. In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration
14. Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials
15. Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients.
16. Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial
17. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis
18. A successful compartmental approach for the treatment of breast cancer brain metastases
19. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans
20. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report
21. Kinetic modelling of myocardial necrosis biomarkers offers an easier, reliable and more acceptable assessment of infarct size
22. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
23. A novel way to manage trastuzumab cardiotoxicity
24. Low to undetectable Omicron BQ.1.1 neutralization by patient’s sera a month after initiation of AZD7442 600 mg
25. Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation
26. Suivi thérapeutique pharmacologique des anti-TNF-α au cours des spondyloarthrites
27. Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group
28. Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study
29. Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients
30. Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial
31. Translational Research in Immune and Inflammatory Diseases: What are the Challenges, Expected Advances, and Innovative Therapies?
32. Recherche translationnelle dans les pathologies immuno-inflammatoires : quels défis, quels progrès attendre, pour quelles innovations thérapeutiques ?
33. Modeling Immunization To Infliximab in Children With Crohn’s Disease Using Population Pharmacokinetics: A Pilot Study
34. Monoclonal Antibodies Targeting the IL-17/IL-17RA Axis: An Opportunity to Improve the Efficiency of Anti-VEGF Therapy in Fighting Metastatic Colorectal Cancer?
35. Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis
36. Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
37. Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease
38. Anticorps monoclonaux à usage thérapeutique : spécificités du développement clinique, évaluation par les agences, suivi de la tolérance à long terme
39. Monoclonal Antibodies for Therapeutic Use: Specific Characteristics of Clinical Development, Evaluation by the Agencies, and Long-term Monitoring of Safety
40. Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target‐mediated drug disposition model
41. A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS)
42. The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition
43. Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model
44. A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)
45. Biomarker kinetic modelling to estimate the effect of conditioning therapies on myocardial ischemiareperfusion injury: PO.041
46. Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer
47. CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen
48. Assessing Cancer Drugs for Reimbursement: Methodology, Relationship between Effect Size and Medical Need
49. Critères et méthodologie d’évaluation au remboursement des anticancéreux
50. Pharmacokinetics of adalimumab in Crohn’s disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.